Related references
Note: Only part of the references are listed.Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake
Lisa K. Dunnwald et al.
CLINICAL CANCER RESEARCH (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Breast Cancer and Hormonal Stimulation: Is Glycolysis the First Sign of Response?
Hannah M. Linden et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Francisco J. Esteva et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Robin L. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
Farrokh Dehdashti et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
Chirayu Shah et al.
CLINICAL CANCER RESEARCH (2009)
Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer A Phase 2 Randomized Study
Matthew J. Ellis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
Lisa K. Dunnwald et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials
Y Tao et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
SK Mohsin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
